Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

Iron Deficiency Anemia Clinical Trial

Official title:

Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron Under Study Protocol 1VIT17044

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04269707
• Other study ID #: 1VIT18045
• Status: Completed
• Phase: Phase 3
• Start date: November 19, 2019
• Est. completion date: January 29, 2021

Study information

• Verified date: March 2022
• Source: American Regent, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron under Study Protocol 1VIT17044

Description:

This is a single arm, open-label, multi-center, multi-national, non-randomized study that will evaluate the efficacy and safety of a one course treatment with FCM in participants who had an unsatisfactory response to oral iron in study 1VIT17044.

Subjects will have an End of Study (EOS) Visit (Day 35) from the 1VIT17044 study to qualify for entry. Subjects will then be screened, meet all inclusion criteria, no exclusion criteria and have a baseline evaluation. Based on the successful completion of the baseline evaluations, subjects will be enrolled and will receive the first dose of FCM (Day 0). The second FCM dose will occur 7 days from the first dose. Subjects will return to the clinic 14 and 28 days post their first dose for laboratory and safety assessments, and at 35 days post the first dose, participants will return to the clinic for final safety and efficacy assessments. Once all assessments are complete the participant will exit the study.

An unsatisfactory response to oral iron (i.e., an increase in hemoglobin (Hgb) of <1 g/dL from baseline) will be defined as non-responders to oral iron treatment. Non-responders who continue to meet all inclusion criteria (including Hgb <11 g/dL) and none of the exclusion criteria will receive 1 course of FCM.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: January 29, 2021
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 18 Years

Eligibility

Inclusion Criteria:

1. Unsatisfactory response to oral iron or those that required a concomitant intervention, (defined as, blood transfusion, use of IV or oral iron outside of protocol, increase in erythropoietin for any reason [Day 0 thru Day 35 of study protocol 1VIT17044], change in IBD treatment).

2. Hgb <11 g/dL

3. Ferritin =300 ng/mL and TSAT <30%

Exclusion Criteria:

1. Known history of hypersensitivity reaction to any component of FCM.

2. History of acquired iron overload, hemochromatosis, or other iron accumulation disorders.

3. History of significant diseases of the liver, hematopoietic system, cardiovascular system, psychiatric disorder, or other conditions which, in the opinion of the investigator, may place a subject at added risk for participation in the study.

4. Any existing non-viral infection.

5. Known history of positive HBsAg or HCV with evidence of active hepatitis.

6. Known history of positive HIV-1/HIV-2 antibodies (anti-HIV).

7. Anemia due to reasons other than iron deficiency (e.g., hemoglobinopathy and vitamin B12 or folic acid deficiency) that has not been corrected.

8. Administration and / or use of an investigational product (drug or device) within 30 days of screening.

9. Alcohol or drug abuse within the past six months.

10. Female participant who is pregnant or lactating, or sexually active females who are of childbearing potential not willing to use an acceptable form of contraceptive precautions during the study.

11. Unable to comply with study procedures and assessments.

Related Conditions & MeSH terms

• Anemia
• Anemia, Iron-Deficiency
• Deficiency Diseases
• Iron Deficiency Anemia

Intervention

Drug:
• Ferric carboxymaltose
IV iron

Locations

Country	Name	City	State
United States	Miami Clinical Research	Miami	Florida
United States	South Florida Research Phase I-IV	Miami Springs	Florida

Sponsors (1)

Lead Sponsor	Collaborator
American Regent, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Hemoglobin From Baseline to Day 35	The change in hemoglobin from Baseline to Day 35 was assessed using paired t-tests (two-sided test, a = 0.05). Baseline hemoglobin was defined as the last hemoglobin obtained before the first dose.	The change in Hgb from baseline to day 35